• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

MS Market to Reach $32.9 BN in 2028, Says Report


The multiple sclerosis (MS) market “has entered an exciting phase, with an upsurge of available treatment options and several promising late-stage pipeline products offering diverse mechanisms of action,” according to data and analytics company, GlobalData.   The market is expected to grow in sales from $19.8bn in 2018 to $32.9bn in 2028 with a compound annual growth rate (CAGR) of 5.2%, thanks the launch of 11 new pipeline agents providing more options for patients and stimulating further competition.   The GlobalData report, Multiple Sclerosis – Global Drug Forecast and Market Analysis to 2028,  states that a further 14 late-stage drug products will launch in the seven major markets-US, France, Germany, Italy, Spain, UK and Japan-during, or shortly after, the forecast period from 2018 to 2028.   The report identifies progressive MS as a significant focus for product development, with seven of the late-stage products targeting this patient group as an initial indication. There is currently a distinct lack of disease modifying therapies (DMT) options for patients with progressive MS subtypes, and these populations remain significantly underserved.   Alessio Brunello, senior pharma analyst at GlobalData, said: “The launch of Mayzent in March 2019 and the potential launch of two other receptor inhibitors-ozanimod and ponesimod-will increase competition in the MS market and these new drugs will take patient share from the approved treatment, Novartis’ Gilenya.”   Noting Novartis’ temporary injunction from generic competition of the US Gilenya patent, which means that the patent will now expire in December 2027, Brunello added that there could still be generic entry in 2022 based on other litigation.   To access the report, click here.    

Related Videos